Development of new diagnostic methods for invasive fungal infection
Publications
Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern.
López, D. 2022. Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern. Front Immunol. 13:832889.
PUBMEDGarcia-Arriaza, J., M. Esteban, and D. López. 2021
Garcia-Arriaza, J., M. Esteban, and D. López. 2021. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines. 9.
PUBMEDCross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins
Tajuelo, A., M. López-Siles, V. Mas, P. Perez-Romero, J. M. Aguado, V. Briz, M. J. McConnell, A. J. Martín-Galiano, and D. López. 2022. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. Int.J.Mol.Sci. 23.
PUBMEDAbundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.
Lorente, E., A. J. Martín-Galiano, D. M. Kadosh, A. Barriga, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2022. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome. J.Proteome.Res. 21:164-171.
DOIPrediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.
López, D. 2022. Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1. Biomedicines. 10.
PUBMED DOIPredicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
Martín-Galiano, A. J., F. Diez-Fuertes, M. J. McConnell, and D. López. 2021. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern. Front Immunol. 12:732693.
PUBMED DOIde la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.
de la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.
PUBMED DOILorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.
Lorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.
PUBMED DOIRedondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
Redondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
PUBMED DOILorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.
Lorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.
PUBMED DOILorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
Lorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
PUBMED DOIMarquez, A., M. Gomez-Fontela, S. Lauzurica, R. Candorcio-Simon, D. Munoz-Martín, M. Morales, M. Ubago, C. Toledo, P. Lauzurica, and C. Molpeceres. 2020. Fluorescence enhanced BA-LIFT for single cell detection and isolation. Biofabrication. 12:025019.
Marquez, A., M. Gomez-Fontela, S. Lauzurica, R. Candorcio-Simon, D. Munoz-Martín, M. Morales, M. Ubago, C. Toledo, P. Lauzurica, and C. Molpeceres. 2020. Fluorescence enhanced BA-LIFT for single cell detection and isolation. Biofabrication. 12:025019.
PUBMED DOILorente, E., C. Palomo, E. Barnea, C. Mir, V. M. Del, A. Admon, and D. López. 2019a. Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. J.Proteome.Res. 18:3512-3520.
Lorente, E., C. Palomo, E. Barnea, C. Mir, V. M. Del, A. Admon, and D. López. 2019a. Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. J.Proteome.Res. 18:3512-3520.
PUBMEDLorente, E., J. Redondo-Anton, A. Martín-Esteban, P. Guasp, E. Barnea, P. Lauzurica, A. Admon, and J. A. López de Castro. 2019. Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis. Mol.Cell Proteomics. 18:2298-2309.
Lorente, E., J. Redondo-Anton, A. Martín-Esteban, P. Guasp, E. Barnea, P. Lauzurica, A. Admon, and J. A. López de Castro. 2019. Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis. Mol.Cell Proteomics. 18:2298-2309.
PUBMED DOIBrait, V. H., F. Miro-Mur, I. Perez-de-Puig, L. Notario, B. Hurtado, J. Pedragosa, M. Gallizioli, F. Jimenez-Altayo, M. Arbaizar-Rovirosa, A. Otxoa-de-Amezaga, J. Monteagudo, M. Ferrer-Ferrer, l. R. de, X, E. Bonfill-Teixidor, A. Salas-Perdomo, A. Hernandez-Vidal, P. Garcia-de-Frutos, P. Lauzurica, and A. M. Planas. 2019. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Circ.Res. 124:279-291.
Brait, V. H., F. Miro-Mur, I. Perez-de-Puig, L. Notario, B. Hurtado, J. Pedragosa, M. Gallizioli, F. Jimenez-Altayo, M. Arbaizar-Rovirosa, A. Otxoa-de-Amezaga, J. Monteagudo, M. Ferrer-Ferrer, l. R. de, X, E. Bonfill-Teixidor, A. Salas-Perdomo, A. Hernandez-Vidal, P. Garcia-de-Frutos, P. Lauzurica, and A. M. Planas. 2019. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Circ.Res. 124:279-291.
DOILópez, D., A. Barriga, E. Lorente, and C. Mir. 2019. Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design. J.Clin.Med. 8.
López, D., A. Barriga, E. Lorente, and C. Mir. 2019. Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design. J.Clin.Med. 8.
PUBMED DOILorente, E., A. Barriga, E. Barnea, C. Palomo, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2019. Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. PLoS.Negl.Trop.Dis. 13:e0007547.
Lorente, E., A. Barriga, E. Barnea, C. Palomo, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2019. Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. PLoS.Negl.Trop.Dis. 13:e0007547.
PUBMED DOIComputational characterization of the peptidome in transporter associated with antigen processing (TAP)-deficient cells.
Martin-Galiano, A. J. and Lopez, D. (2019) Computational characterization of the peptidome in transporter associated with antigen processing (TAP)-deficient cells. PLoS.ONE. 14, e0210583.
PUBMED DOIProteomics analysis reveals that structural proteins of the virion core and involved in gene expression are the main source for HLA class II ligands in vaccinia virus-infected cells.
Lorente, E., Martin-Galiano, A. J., Barnea, E., Barriga, A., Palomo, C., Garcia-Arriaza, J., Mir, C., Lauzurica, P., Esteban, M., Admon, A., and Lopez, D. (2019) Proteomics analysis reveals that structural proteins of the virion core and involved in gene expression are the main source for HLA class II ligands in vaccinia virus-infected cells. J.Proteome.Res. 18(9):3512-3520
PUBMED DOIGuasp, P., E. Lorente, A. Martín-Esteban, E. Barnea, P. Romania, D. Fruci, J. J. W. Kuiper, A. Admon, and J. A. López de Castro. 2019. Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-Associated HLA-B*51 Peptidome. Mol.Cell Proteomics.
Guasp, P., E. Lorente, A. Martín-Esteban, E. Barnea, P. Romania, D. Fruci, J. J. W. Kuiper, A. Admon, and J. A. López de Castro. 2019. Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-Associated HLA-B*51 Peptidome. Mol.Cell Proteomics.
PUBMED DOIFontela, M. G., L. Notario, E. Alari-Pahissa, E. Lorente, and P. Lauzurica. 2019
Fontela, M. G., L. Notario, E. Alari-Pahissa, E. Lorente, and P. Lauzurica. 2019. The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1. Genes (Basel) 10.
PUBMED DOIAdditional Information
RECENT COLLABORATIONS
1. Dr. Marco Teixeira. Visiting professor at the University of Brasilia (UnB). Affiliated researcher at Northern Arizona University (NAU)
2. Dr. Alexandre Alanio. Researcher at Hôpital St. Louis, Paris. France
3. Dr. Dunja Wilmes. Researcher at the Robert Koch Institute. Sedan. Germany.
4. Dr. Paula Sampaio. Center for Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal
5. Dr. Rosely Zancope-Oliveira. Professor at the Oswaldo Cruz Foundation. Rio de Janeiro, Brazil.
6. Dr. Ana Cecilia Mesa Arango. Professor at the University of Antioquia. Medellin. Colombia
7. Dr. Néstor Pakasa. Professor, Kinshasa University Hospital, Kinshasa, Democratic Republic of the Congo
8. Dr. David aka. Researcher at the Félix Houphouët-Boigny University, Abidjan, Ivory Coast
PATENTS
a) Registered industrial property title: “Development of a rapid method for the diagnosis of histoplasmosis and/or paracoccidioidomycosis by multiplex Real-Time PCR with Molecular Beacon type probe initiators.” Inventors: María José Buitrago Serna; Manuel Cuenca Estrella; Juan Luis RodriguezTudela; Alicia Gómez López. Rights holder entity: Carlos III Health Institute. Application number: P200802665. Country of registration: Spain. Registration date: 09/19/2008. Grant date: 09/14/2011
b) Registered industrial property title: Riboflavin-synthese in Ashbya gossypii. Inventors/authors/breeders: Jose Luis Revuelta Doval; María José Buitrago Serna; Maria de los Angeles Santos García. Rights holder entity: BASF Aktiengesellschaft. Application number: CA 2186403. Registration date: 03/25/1994. Grant date: 01/24/2006
c) Registered industrial property title: Riboflavin-Synthese in Hefen. Inventors/authors/breeders: Jose Luis Revuelta Doval; Jose Javier García Ramírez; Maria de Los Angeles Santos García; Gloria Angélica González; María José Buitrago Serna. Rights holder entity: BASF Aktiengesellschaft. Application number: EP19940901793. Registration date: 11/19/199. Grant date: 05/07/1997
DIRECTION OF DOCTORAL THESES
1. Title: Development of new methods for diagnosis and identification of fungal species that cause opportunistic pneumonia. Implementation entity: Complutense University-ISCIII. Student: Clara Valero Fernández. Qualification obtained: Excellent Cum Laude. Defense date: 05/19/2017
2. Title: Development and Validation of diagnostic techniques for invasive fungal infection. Implementation entity: Complutense University of Madrid-ISCIII. Student: Sara Gago Prieto. Grade obtained: Excellent cum laude. Defense date: 07/18/2014
3. Title: Development of techniques based on real-time PCR for the diagnosis of invasive fungal infections. Implementation entity: Complutense University of
Madrid-ISCIII. Student: Leticia Bernal Martinez. Grade obtained: Excellent cum laude. Defense date: 2010
RECENT COLLABORATIONS
1. Dr. Marco Teixeira. Visiting professor at the University of Brasilia (UnB). Affiliated researcher at Northern Arizona University (NAU)
2. Dr. Alexandre Alanio. Researcher at Hôpital St. Louis, Paris. France
3. Dr. Dunja Wilmes. Researcher at the Robert Koch Institute. Sedan. Germany.
4. Dr. Paula Sampaio. Center for Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal
5. Dr. Rosely Zancope-Oliveira. Professor at the Oswaldo Cruz Foundation. Rio de Janeiro, Brazil.
6. Dr. Ana Cecilia Mesa Arango. Professor at the University of Antioquia. Medellin. Colombia
7. Dr. Néstor Pakasa. Professor, Kinshasa University Hospital, Kinshasa, Democratic Republic of the Congo
8. Dr. David aka. Researcher at the Félix Houphouët-Boigny University, Abidjan, Ivory Coast
PATENTS
a) Registered industrial property title: “Development of a rapid method for the diagnosis of histoplasmosis and/or paracoccidioidomycosis by multiplex Real-Time PCR with Molecular Beacon type probe initiators.” Inventors: María José Buitrago Serna; Manuel Cuenca Estrella; Juan Luis RodriguezTudela; Alicia Gómez López. Rights holder entity: Carlos III Health Institute. Application number: P200802665. Country of registration: Spain. Registration date: 09/19/2008. Grant date: 09/14/2011
b) Registered industrial property title: Riboflavin-synthese in Ashbya gossypii. Inventors/authors/breeders: Jose Luis Revuelta Doval; María José Buitrago Serna; Maria de los Angeles Santos García. Rights holder entity: BASF Aktiengesellschaft. Application number: CA 2186403. Registration date: 03/25/1994. Grant date: 01/24/2006
c) Registered industrial property title: Riboflavin-Synthese in Hefen. Inventors/authors/breeders: Jose Luis Revuelta Doval; Jose Javier García Ramírez; Maria de Los Angeles Santos García; Gloria Angélica González; María José Buitrago Serna. Rights holder entity: BASF Aktiengesellschaft. Application number: EP19940901793. Registration date: 11/19/199. Grant date: 05/07/1997
DIRECTION OF DOCTORAL THESES
1. Title: Development of new methods for diagnosis and identification of fungal species that cause opportunistic pneumonia. Implementation entity: Complutense University-ISCIII. Student: Clara Valero Fernández. Qualification obtained: Excellent Cum Laude. Defense date: 05/19/2017
2. Title: Development and Validation of diagnostic techniques for invasive fungal infection. Implementation entity: Complutense University of Madrid-ISCIII. Student: Sara Gago Prieto. Grade obtained: Excellent cum laude. Defense date: 07/18/2014
3. Title: Development of techniques based on real-time PCR for the diagnosis of invasive fungal infections. Implementation entity: Complutense University of
Madrid-ISCIII. Student: Leticia Bernal Martinez. Grade obtained: Excellent cum laude. Defense date: 2010